By: Gutierrez H.B. No. 3299

A BILL TO BE ENTITLED

AN ACT
relating to a study regarding the provision of the drug palivizumab
through the Medicaid vendor drug program to premature newborns.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. The Department of State Health Services shall
conduct a study to determine the appropriateness of criteria set
for approval for dosage to premature newborns:
(1) whether a newborn should meet 3 criteria before
administration of drug is approved;
(2) access to quality of medical care for a newborn
receiving this drug;
(3) any other factors the Agency considers relevant.
SECTION 2. No later than December 1, 2014, The Texas
Education Agency shall:
(1) publish the results of the study required by this
Act on the commission's available Internet website; and
(2) deliver the results of the study required by this
<pre>Act to:</pre>
(A) the governor, the lieutenant governor, the
speaker of the house of representatives, and each committee of each
house of the legislature that has jurisdiction over state health
<u>services</u>

SECTION 3. This Act takes effect September 1, 2013.

23